Suppr超能文献

病毒感染可消除共刺激阻断诱导的 CD8(+) T 细胞缺失。

Viral infection abrogates CD8(+) T-cell deletion induced by costimulation blockade.

作者信息

Turgeon N A, Iwakoshi N N, Phillips N E, Meyers W C, Welsh R M, Greiner D L, Mordes J P, Rossini A A

机构信息

Departments of Medicine, Pathology, and Surgery, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.

出版信息

J Surg Res. 2000 Sep;93(1):63-9. doi: 10.1006/jsre.2000.5962.

Abstract

BACKGROUND

Treatment with a single donor-specific transfusion (DST) plus a brief course of anti-CD154 monoclonal antibody (mAb) prolongs skin allograft survival in mice. It is known that prolongation of allograft survival by this method depends in part on deletion of alloreactive CD8(+) T cells at the time of tolerance induction. Recent data suggest that infection with lymphocytic choriomeningitis virus (LCMV) abrogates the ability of this protocol to prolong graft survival.

METHODS

To study the mechanism by which viral infection abrogates allograft survival, we determined (1) the fate of tracer populations of alloreactive transgenic CD8(+) T cells and (2) the duration of skin allograft survival following treatment with DST and anti-CD154 mAb in the presence or absence of LCMV infection.

RESULTS

We confirmed that treatment of uninfected mice with DST and anti-CD154 mAb leads to the deletion of alloreactive CD8(+) T cells and is associated with prolongation of skin allograft survival. In contrast, treatment with DST and anti-CD154 mAb in the presence of intercurrent LCMV infection was associated with the failure to delete alloreactive CD8(+) T cells and with the rapid rejection of skin allografts. The number of alloreactive CD8(+) cells actually increased significantly, and the cells acquired an activated phenotype.

CONCLUSIONS

Interference with the deletion of alloreactive CD8(+) T cells mediated by DST and anti-CD154 mAb may in part be the mechanism by which viral infection abrogates transplantation tolerance induction.

摘要

背景

用单次供体特异性输血(DST)加短期抗CD154单克隆抗体(mAb)治疗可延长小鼠皮肤同种异体移植的存活时间。已知通过这种方法延长同种异体移植存活时间部分取决于在诱导耐受时清除同种异体反应性CD8(+) T细胞。最近的数据表明,淋巴细胞性脉络丛脑膜炎病毒(LCMV)感染会消除该方案延长移植物存活的能力。

方法

为了研究病毒感染消除同种异体移植存活的机制,我们确定了(1)同种异体反应性转基因CD8(+) T细胞示踪群体的命运,以及(2)在有或无LCMV感染的情况下,用DST和抗CD154 mAb治疗后皮肤同种异体移植的存活持续时间。

结果

我们证实,用DST和抗CD154 mAb治疗未感染的小鼠会导致同种异体反应性CD8(+) T细胞的清除,并与皮肤同种异体移植存活时间的延长相关。相比之下,在同时存在LCMV感染的情况下用DST和抗CD154 mAb治疗与未能清除同种异体反应性CD8(+) T细胞以及皮肤同种异体移植的快速排斥相关。同种异体反应性CD8(+)细胞的数量实际上显著增加,并且这些细胞获得了活化表型。

结论

干扰由DST和抗CD154 mAb介导的同种异体反应性CD8(+) T细胞的清除可能部分是病毒感染消除移植耐受诱导的机制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验